CRESSKILL, N.J. and JERUSALEM, Israel, June 7, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:
Clinical TMS Society Annual Meeting from June 10-12. The Annual Meeting of the Clinical TMS Society provides a unique opportunity to connect with TMS providers and researchers from around the world. Seven poster presentations will highlight the benefits and potential of Deep TMS™ treatment for mental health disorders. Additionally, the Company will be hosting two showcase presentations featuring novel research and the clinical utility of Deep TMS.
Psych Congress Elevate: Virtual Experience from June 11- 13. The global conference brings together early career and future-focused clinicians presenting a unique opportunity to connect on the latest innovations, therapies, and research. Deep TMS provider David Feifel MD, PhD, Director at Kadima Neuropsychiatry Institute, will be participating in the showcase presentation, “Beyond Depression: Evidence for Deep TMS in OCD and Smoking Cessation” on Friday, June 11, 2021 from 5:00-5:30 p.m. EST.
“We are excited to connect and participate in these two society meetings, both focused on advancing the field of mental health with cutting edge treatments and strategies,” said Christopher Boyer, Vice President of Global Marketing at BrainsWay. “Those attending have a direct and positive impact on patient lives and are aligned with our commitment to advancing noninvasive treatment options for mental health disorders.”
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.
Contacts: BrainsWay: Scott Areglado SVP and Chief Financial Officer Scott.Areglado@BrainsWay.com
Investors: Bob Yedid LifeSci Advisors (646) 597-6989 Bob@LifeSciAdvisors.com
Media Contact: Will Johnson (201) 465-8019 Brainsway@antennagroup.com
Comentarios